National Comprehensive Cancer Network



About NCCN

Thyroid Carcinoma Panel - Disclosures as of 12/14/2012

View NCCN Management Team Disclosures | View NCCN Guidelines Staff Disclosures | View NCCN ORP Staff Disclosures

Panel Member Clinical Research Support Advisory Boards, Speakers Bureau, Expert Witness, or Consultant Patent, Equity, or Royalty Other Date Completed

Douglas W. Ball, MD

Eisai Inc.;
Exelixis Inc.;
Roche USA

Exelixis Inc.

None

None

12/7/2011

David Byrd, MD

None

None

None

None

3/4/2013

Paxton Dickson, MD

None

None

None

None

8/27/2012

Quan-Yang Duh, MD

None

None

None

None

6/24/2012

Hormoz Ehya, MD

None

Eli Lilly and Company

None

None

12/11/2012

William B. Farrar, MD

None

None

None

None

6/18/2012

Lauren Gallagher, RPh, PhD

None

None

None

None

6/5/2012

Kristina M. Gregory, RN, MSN, OCN

None

None

None

None

10/23/2012

Robert I. Haddad, MD

None

None

None

None

6/8/2011

Megan Haymart, MD

None

None

None

None

9/6/2012

Miranda Hughes, PhD

None

None

None

None

4/10/2013

Jason P. Hunt, MD

None

None

None

None

10/18/2011

Fouad Kandeel, MD, PhD

None

None

None

None

8/17/2012

Peter Kopp, MD

None

None

None

None

8/30/2012

Dominick M. Lamonica, MD

None

None

None

None

6/18/2012

William M. Lydiatt, MD

None

None

None

None

5/2/2012

Judith C. McCaffrey, MD

None

None

None

None

7/26/2012

Joan S. McClure, MS

None

None

None

None

7/23/2012

Nicole McMillian, MS

None

None

None

None

3/27/2013

Jeffrey F. Moley, MD

AstraZeneca Pharmaceuticals LP;
Exelixis Inc.

Exelixis Inc.

None

None

10/8/2012

Lee Parks, MD

None

None

None

None

11/9/2012

John A. Ridge, MD, PhD, FACS

None

None

None

None

3/8/2013

Randall P. Scheri, MD

None

None

None

None

4/18/2012

Jatin P. Shah, MD, PhD

None

None

None

None

6/5/2012

Steven I. Sherman, MD

Amgen Inc.;
AstraZeneca Pharmaceuticals LP;
Genzyme Corporation;
National Cancer Institute;
V Foundation for Cancer Research;
Pfizer Inc.

AstraZeneca Pharmaceuticals LP;
Bayer HealthCare;
Eisai Inc.;
Eli Lilly and Company;
Exelixis Inc.;
Novo Nordisk;
Veracyte;
Pfizer Inc.

None

None

8/25/2011

Cord Sturgeon, MD

None

None

None

None

6/18/2012

R. Michael Tuttle, MD

None

AstraZeneca Pharmaceuticals LP;
Exelixis Inc.;
Genzyme Corporation;
Novo Nordisk;
Veracyte

None

None

10/5/2012

Steven G. Waguespack, MD

Eisai Inc.;
Novartis Pharmaceuticals Corporation;
Hoffman La Roche

None

None

None

7/24/2012

Thomas N. Wang, MD

None

None

None

None

7/20/2012

Lori J. Wirth, MD

None

Bayer HealthCare;
Novartis Pharmaceuticals Corporation

None

None

4/9/2012

 

About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0260
Copyright © 2012 National Comprehensive Cancer Network, All Rights Reserved